New treatment pathways for hepatitis C

Burnet Institute

28 July, 2021

Image: Hepatitis C viral load testing on GeneXpert by Than Sitt Charity Clinic laboratory technician (Credit: Kyaw Win Hlaing)

A newly published Burnet Institute study has demonstrated the feasibility and effectiveness of simplified clinical pathways for treatment of hepatitis C (HCV) in Myanmar.

Conducted between January 2019 and August 2020, the study provides endorsement for a ‘one-stop-shop’ model for HCV treatment and care that could be applied more widely in Myanmar and in other low- and middle-income settings globally.

The study was done in partnership with FIND, the global diagnostics alliance as part of the HEAD-Start (Hepatitis Elimination through Access to Diagnostics) portfolio, funded by Unitaid, and published in the journal Liver International.

Lead author, Burnet Research Assistant and PhD candidate Bridget Draper, said the study involved the use of rapid tests, point-of-care GeneXpert diagnostic testing and direct-acting antiviral prescription by general practitioners at decentralised primary care clinics.

The availability of new highly effective pan-genotypic treatments obviates the need for patients to undergo genotyping.

Patients no longer need to visit specialists in hospitals for transient elastography (for example, a FibroScan) for diagnosing cirrhosis as simple blood tests that are widely available used to calculate the APRI score are sufficient.

Ms Draper said the study, involving more than 600 participants from two sites in Yangon – one for people who inject drugs (PWID) run by Burnet Institute Myanmar, and the other for people with liver disease, run by Myanmar Liver Foundation – produced outstanding results with high rates of retention across the cascade of care.

“Almost everyone who started treatment, finished treatment, we didn’t lose anyone before starting treatment,” Ms Draper said.

“We also found really good cure rates above 90 percent for everyone, and a really short time – a median of three days – from testing to starting treatments, which is quite quick.”

Ms Draper said the high retention rate of patients in care from the start to finish of treatment is significant.

“The more we lose people throughout the cascade of care, the more expensive it is to get anyone to start treatment, finish treatment, and achieve a cure,” she said.

“Keeping people throughout the care cascade is cost effective, which is important in settings where there are limited resources available to treat and cure people of hepatitis C.

“This study showed that a one-stop-shop model of care led by GPs can provide a really convenient model of care for the patients.”

Ms Draper said she believes most of what was implemented and learned from the study could be easily applied or adapted to other settings.

“We had to get extra equipment, for example, to make sure there was continuous electricity supply at the sites, and ensure stock was stored safely in really high temperatures and humidity, she said.

“These sorts of challenges are the same globally for low- and middle-income countries in particular and would need to be adapted, but the key components are really quite easy to implement elsewhere and should have similar success.”

Study supervisor, Professor Margaret Hellard AM, said the study provides an important pathway forward in global efforts to eliminate hepatitis C as a global health threat.

“The vast majority of hepatitis C infections occur in low- and middle-income countries. This work shows that a simple one-stop-shop approach – where testing and treatment occurs in the community – is highly effective,” Professor Hellard said.

The study findings support Myanmar’s national hepatitis C guidelines and the development of formal recommendations from the World Health Organization on simplified service delivery to support the expansion of HCV treatment and testing in other low- and middle-income countries.

HCV is bloodborne and most commonly transmitted through exposure to blood. Infections are usually asymptomatic and a major cause of liver damage and liver cancer.

Globally, an estimated 58 million people have chronic hepatitis C virus infection including more than one million in Myanmar, where the infection rate among PWID is high, at 56 percent.

Find out more about Burnet’s hepatitis research and how you can support this important work.

Contact Details

For more information in relation to this news article, please contact:

Bridget Draper

Research Assistant




Subscribe to News

Subscribe to receive our latest news: